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Abstract
Background: In Brazil, heart failure leads to approximately 25,000 deaths per year. Abnormal
calcium handling is a hallmark of heart failure and changes in genes encoding for proteins involved
in the re-uptake of calcium might harbor mutations leading to inherited cardiomyopathies.
Phospholamban (PLN) plays a prime role in cardiac contractility and relaxation and mutations in
the gene encoding PLN have been associated with dilated cardiomyopathy. In this study, our
objective was to determine the presence of the -36A>C alteration in PLN gene in a Brazilian
population of individuals with HF and to test whether this alteration is associated with heart failure
or with a worse prognosis of patients with HF.
Methods: We genotyped a cohort of 881 patients with HF and 1259 individuals from a cohort of
individuals from the general population for the alteration -36A>C in the PLN gene. Allele and
genotype frequencies were compared between groups (patients and control). In addition,
frequencies or mean values of different phenotypes associated with cardiovascular disease were
compared between genotypic groups. Finally, patients were prospectively followed-up for death
incidence and genotypes for the -36A>C were compared regarding mortality incidence in HF
patients.
Results: No significant association was found between the study polymorphism and HF in our
population. In addition, no association between PLN -36A>C polymorphism and demographic,
clinical and functional characteristics and mortality incidence in this sample of HF patients was
observed.
Conclusion: Our data do not support a role for the PLN -36A>C alteration in modulating the
heart failure phenotype, including its clinical course, in humans.
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Background
Congestive heart failure resulting from cardiomyopathies
is a serious malady and a leading cause of human morbid-
ity and mortality[1]. In Brazil, heart failure (HF) is respon-
sible for approximately 25,000 deaths per year [2] and is
associated with considerable morbidity, since patients
with HF undergo frequent hospital readmissions, which
are higher in those of lower socioeconomic strata.
Although HF is a common endpoint for many forms of
cardiovascular diseases, one of the most common cause of
congestive heart failure is the dilated cardiomyopathy
(DC), affecting 40 people in every 100,000 of the popula-
tion [3]. DC is characterized by ventricular chamber
enlargement and systolic dysfunction with normal left
ventricular (LV) wall thickness [4]. DC may be inherited
as a dominant disorder associated with a range of already
described genetic defects [5]. Despite genetic heterogene-
ity, abnormal calcium handling is a hallmark of DC [6].
Therefore, changes in genes encoding for proteins
involved in the re-uptake of calcium might harbor muta-
tions leading to cardiomyopathies [7,8].
Phospholamban (PLN) plays a prime role in cardiac con-
tractility and relaxation [9] and mutations in the gene
encoding for PLN have been associated with DC. Moreo-
ver, specific genotype-phenotype associations may pre-
dicted by PLN mutations [10-13].
The genetic variant (A>C) at position AF177763.
1:g.203A>C (at -36 bp relative to the PLN transcriptional
start site: -36A>C) of the PLN gene has contradictory find-
ings in the literature. The first study to describe it [8],
found an allelic frequency of 0.6% in DC patients and
2.5% in healthy control individuals. Furthermore, after a
functional in vitro assay development, the authors did not
find an altered transcription activity rate associated with
the presence of any particular allele. In contrast, Haghighi
et al [14], found this alteration in an allelic frequency of
2.9% and 0.2% in DC patients and in healthy control
individuals, respectively. In this later study, they sug-
gested, after in vitro functional assays, that this transition
might contribute to depressed contractility and acceler-
ated functional deterioration in heart failure.
In this study, our objective was to determine the presence
of the -36A>C alteration in the PLN gene in a Brazilian
population of individuals with HF and to test whether this
alteration is associated with a worse prognosis leading to
increased structural heart modifications and a worse prog-
nosis in patients with HF.
Methods
Study design
Patients from an ongoing inception cohort of patients
with heart failure were included in the present study
between 1995 and 2005, submitted to sequential echocar-
diographic evaluation and to clinical follow-up for death
and/or heart transplantation. Eight hundred and eighty-
five patients were studied in the General Outpatient Clinic
of the Heart Institute of São Paulo University Medical
School. The diagnosis of heart failure was made according
to previously published criteria [15]. The classification of
the etiology of heart failure followed previous recommen-
dations [16,17].
Inclusion criteria
Patients with symptomatic heart failure of different etiol-
ogies and left ventricular ejection fraction ≤ 45% on two-
dimensional transthoracic Doppler echocardiography
were eligible for the study. Patients were also evaluated for
surgical treatment of heart failure, including heart trans-
plantation. Specifically, patients with heart failure due to
valve disease enrolled in the study were those with severe
left ventricular dysfunction to the point that they would
not be eligible for valve repair or replacement, but rather
candidates for heart transplantation.
Exclusion criteria
Patients with heart failure due to valve disease that would
be candidates for conventional surgical treatment, such as
valve repair or replacement; patients with hypertrophic
cardiomyopathy, chronic obstructive pulmonary disease,
recent myocardial infarction and unstable angina were
excluded. In addition, patients with severe renal or
hepatic dysfunction, severe peripheral artery disease, cere-
brovascular disease, active infection, coexisting neoplasm
and active peptic ulcer disease were also excluded [18].
Control population – General population of Vitória/ES, 
Brazil
A cross-sectional study of risk factors for cardiovascular
diseases was performed in the urban population of Vito-
ria, Brazil, using the WHO-MONICA project guidelines.
The study design was based on cross-sectional research
methodology and was developed by means of surveying
and analyzing socioeconomic and health data in a proba-
bilistic sample of residents aged 25 to 64 years from the
municipality of Vitoria, ES, Brazil. The population was
randomized and the sample was socioeconomically, geo-
graphically and demographically representative of the res-
idents of this municipality. A selection of 2,268
residential homes located in Vitoria was made and these
were visited. The project received approval from the Ethics
Committee of the Biomedical Center of Universidade Fed-
eral do Espírito Santo (UFES). The selected individuals
were asked to attend the Cardiovascular Investigation
Clinic of the University Hospital for tests to be performed
on the following day. Of the total sample, 1,577 individ-
uals attended. Participants were submitted to physical
examination. Major cardiovascular risk factors such as
smoking habits, alcohol intake, sedentarism, diabetes andBMC Cardiovascular Disorders 2009, 9:33 http://www.biomedcentral.com/1471-2261/9/33
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hypertension were inquired. Blood glucose, total choles-
terol, lipoprotein fractions, and triglycerides were assayed
by standard techniques in a 12 hour fasting blood sam-
ple[19].
Left ventricular function assessment
Sequential left ventricular ejection fraction was deter-
mined by M-mode echocardiography. In some patients
two-dimensional method was employed, using Simpson.
The evaluation of the left ventricular function was per-
formed by the echocardiography staff in a blinded way in
relation to the genotypes and was conducted according to
previously published recommendations [20].
Genotype determination
Extraction of genomic DNA was performed from leuko-
cytes separated from whole blood using a standard
method [21]. The genomic reference with GenBank acces-
sion number AF177763.1 [GeneBank: AF177763.1] was
used to retrieve the PLN sequence corresponding to prox-
imal promoter and exon 1. The -36A>C alteration was
detected by a polymerase chain reaction (PCR) technique.
We used a web program http://helix.wustl.edu/dcaps/
dcaps.html to design the forward primer 5'-ATGTGACAT-
CATAAGACCTCCCTCG-3' with 1 mismatch nucleotide
(in bold – at position -38 of the gene) that abolish a TaqI
restriction site in the mutated sequence. The reverse
primer 5'-ATTTCAAAGTTGTCTCATT-3' was designed
using the PrimerSelect program (Lasergene®). The digested
fragments by TaqI were undertaken in a blinded way after
the samples had been separated with electrophoresis on a
3% agarose gel and stained with ethidium bromide (1 μg/
ml).
Statistical analysis
Data are presented as means ± SDs for continuous varia-
bles and as frequencies for categorical variables. Differ-
ences in baseline characteristics among groups were
analyzed using Student's t test for continuous variables
and the Chi-square test for categorical variables. Survival
curves were calculated for each genotype with the Kaplan-
Meier method, and differences between the curves were
evaluated with the log-rank statistic. Multivariable tests
were performed if an association was detected adjusting
for possible confounders. The risk for events was
expressed as an odds ratio with 95% confidence intervals.
Statistical analyses were performed with SPSS software. A
p value < 0.05 was considered significant.
Ethics
The study protocol was approved by the Ethics Committee
for Medical Research on Human Beings of the Hospital das
Clínicas  from University of São Paulo Medical School.
Signed informed consent was obtained from all partici-
pants.
Results
After genotyping 881 patients with HF and 1259 general
control individuals we found the alteration in 51 HF
patients (three homozygotes) and 63 individuals from the
general population (two homozygotes), because of the
small number of homozygote individuals, they were
joined with heterozygote for further analysis. Allelic fre-
quency was 3,1% in HF patients and 2,5% in the general
control sample. Genotypic frequencies were not signifi-
cantly different when comparing HF and normal individ-
uals (p = 0,50).
Analyzing only individuals with HF, the comparison of
baseline demographic and clinical characteristics did not
reveal any statistically significant difference between the
genotype groups (Table 1). The same is seen for the gen-
eral control population, with the exception of ethnicity
(Table 2).
Next, we tested the association between -36A>C geno-
types and functional characteristics acquired through
baseline echocardiography examination and, again, we
did not observe any significant association for the HF and
the general control population. The data are shown in
tables 3 and 4, respectively.
Genotypic frequency distribution within the HF sample
was not significantly different when comparing different
etiologies (Table 5).
No difference was observed in the use of medications for
heart failure between genotypic groups at baseline (data
not shown), eliminating this as a potential confounder in
our longitudinal analysis.
Finally, the mortality or heart transplantation incidence
was not different between individuals harboring the allele
potentially associated with decreased functional status
(Figure 1).
Discussion
The PLN -36A>C is not a polymorphism described in any
database. It was first described in the Spanish population
with an allelic frequency of 0,5% (n = 85) in patients with
DC and 2,5% (n = 120) in a healthy control population
[8]; later it was described in the Greek and Caucasian pop-
ulations with an allelic frequency of 3,7% (n = 218) and
1,8% (n = 163) in DC patients, respectively. In the Greek
population, the variation displayed an allelic frequency of
0,16% (n = 296) in healthy controls [14]. Herein, we haveBMC Cardiovascular Disorders 2009, 9:33 http://www.biomedcentral.com/1471-2261/9/33
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genotyped 881 HF patients, and 1259 general control
individuals, the allelic frequencies found were 3,06% and
2,5%, respectively. Comparing the genotype frequencies,
we observed that there was no difference between cases
and controls studied. In addition, analyzing the allelic fre-
quencies of the different etiologies enrolled, we do not
observe any difference between, suggesting there is no
specific modulation of this particular genetic variant in
any particular etiological process leading to cardiomyop-
athy.
There are conflicting findings in the literature regarding a
potential functional effect of the studied polymorphism.
Haghighi et al, have argued that due to the alteration prox-
imity to a putative TATA box (12 nucleotides) it could
play a role in gene expression regulation. In their study,
they found an increased transcriptional activity and sug-
gested that this was due to the lost of a putative glucocor-
ticoid receptor binding site. On the other hand, Medin et
al, 2007, did not find an altered transcriptional activity
associated with any particular allele.
Here we have observed a similar genotypic distribution
between men and women, and among the different heart
failure etiologies suggesting a homogeneous distribution
throughout the HF population stratum (Table 1). Like-
wise, we observed the same homogeneous distribution in
our general population sample, data is shown in table 2,
Table 1: Clinical and demographic characteristics of the HF sample according to genotype.
AA AC + CC P value
Number 830 51 -
Age, years 52.74 ± 14.76 56.16 ± 13.33 -
Gender
Male(%) 67.63 64.71 0.66
Ethnicity (%) 0.86
Blacks 95.5 4.5
Mulattos 95.5 4.5
Whites 93.6 6.4
Others 100 0
Etiology (%) 0.55
Chagasic 92.9 7.1
Idiopathic 95.7 4.3
Hypertensive 95.9 4.1
Ischemic 93.6 6.4
HF due to valve disease 91.1 8.9
Others 93.9 6.1
Biochemical
Serum sodium (mg/dL) 136.79 ± 4.49 135.90 ± 4.84 0.28
Hemoglobin (mg/dL) 13.07 ± 2.14 13.03 ± 2.07 0.90
Total Cholesterol (mg/dL) 192.03 ± 50.51 192.76 ± 46.43 0.93
Triglycerides (mg/dL) 126.05 ± 76.44 149.42 ± 86.34 0.72
HDL (mg/dL) 44.09 ± 14.57 44.49 ± 15.93 0.87
LDL (mg/dL) 121.31 ± 42.62 118.89 ± 38.91 0.74
Creatinin (mg/dL) 1.32 ± 0.65 1.48 ± 0.52 0.09
Glycemia (mg/dL) 112.78 ± 54.36 114.79 ± 50.68 0.81
BMI (kg/m2) 25.36 ± 4.98 26.2 ± 4.97 0.34
Heart Rate (pm) 79.73 ± 13.16 79.38 ± 11.01 0.61
Diastolic Blood Pressure (mmHg) 76.26 ± 18.57 73.66 ± 13.7 0.45
Systolic Blood Pressure (mmHg) 122.12 ± 31.36 118.97 ± 24.83 0.59BMC Cardiovascular Disorders 2009, 9:33 http://www.biomedcentral.com/1471-2261/9/33
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Table 2: Clinical and demographic characteristics for the general control population sample according to genotype.
AA AC + CC P value
Number 1198 61 -
Age, years 45 ± 11 44 ± 11 -
Gender
Male (%) 45.4 45.9 0.94
Ethnicity (%) 0.006
Blacks 100 0
Mulattos 96.8 3.2
Whites 92.6 7.4
Others 93.8 6.3
Biochemical
Total Cholesterol (mg/dL) 205.82 ± 89.68 199.7 ± 63.74 0.47
Triglycerides (mg/dL) 118.5 ± 96.15 110.62 ± 79.23 0.46
HDL (mg/dL) 59.84 ± 36.92 60.66 ± 38.68 0.87
Creatinin (mg/dL) 1.89 ± 2.11 1.93 ± 2,12 0.88
Glycemia (mg/dL) 93.32 ± 39.12 86.72 ± 30.72 0.11
BMI (kg/m2) 26.37 ± 4.93 27.16 ± 6.38 0.34
Heart Rate (pm) 70.96 ± 11.26 72.59 ± 9 0.48
Diastolic Blood Pressure (mmHg) 83.39 ± 13.43 82.13 ± 12.43 0.44
Systolic Blood Pressure (mmHg) 127.07 ± 21.99 124.05 ± 18.37 0.22
Table 3: Functional data for the HF sample according to genotype
AA AC + CC P Value
Interventricular septum, mm 9.03 ± 1.98 9.42 ± 2.19 0.24
LV posterior wall, mm 8.93 ± 1.73 9.42 ± 2.22 0.14
LV diastolic diameter, mm 67.52 ± 12.06 65.4 ± 10.47 0.18
LV systolic diameter, mm 57.13 ± 13.64 55.1 ± 12.62 0.33
LV ejection fraction, (%) 40.43 ± 14.87 44.7 ± 15.78 0.08
Aortic diameter, mm 32.91 ± 5.03 34.5 ± 6.03 0.88
LA diameter, mm 46.95 ± 8.56 45.40 ± 7.73 0.19
RV diameter, mm 26.52 ± 7.05 25.03 ± 8.57 0.35
LV mass, g 251.2 ± 93.5 264.4 ± 106.3 0.53
LV – left ventricle, LA – left atrium, RV – right ventricleBMC Cardiovascular Disorders 2009, 9:33 http://www.biomedcentral.com/1471-2261/9/33
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excepting for the distribution among ethnic groups where
we do not see the presence of the variation in black indi-
viduals.
We also observed a lack of association between the poly-
morphism and clinical (Table 1) and echocardiography
(Table 3) data. Again, the same result was found in the
general population in table 2 (clinical) and 4 (echocardi-
ography), excepting for the left atrium diameter. How-
ever, as this was the unique characteristic with a
significant association among nine correlated characteris-
tics with non-significative associations, we believe this is a
false-positive finding.
Finally, the Kaplan-Meier survival curves were not signifi-
cantly different (Figure 1) between groups. This indicated
that, despite a potentially functional variant regarding
gene transcription rate, no association exists with an
increased mortality incidence. All the results previously
described were not influenced by a differential use of
heart failure medications.
Conclusion
There is no difference between the frequency of the stud-
ied variation between HF and the general population indi-
viduals. Taken together, our data do not support a role for
the PLN -36A>C alteration in modulating the phenotype
or clinical course of heart failure.
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